Portico Next Generation Approval Study

Running, not enrolling · Not applicable

Conditions studied: Symptomatic Severe Aortic Stenosis

In brief

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

Key facts

Study ID
NCT04011722
Run by
Abbott Medical Devices
People needed
333
Starts
2019-09-17
Expected to finish
2033-01-01
Last updated by the study team
2026-07-21

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.